Results 111 to 120 of about 15,396 (182)

Immunogenicity and Safety of the Higher-Valent Pneumococcal Conjugate Vaccine vs the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials. [PDF]

Open Forum Infect Dis
Ngamprasertchai T, Ruenroengbun N, Kajeekul R.   +2 more
europepmc   +1 more source

Clinical Features and Outcomes of Pneumococcal Bacteremia in Children With Sickle Cell Disease in the Pneumococcal Conjugate Vaccine Era. [PDF]

Pediatr Blood Cancer
Yee ME, Abel L, Kalmus G, Patel A, Elmontser M, Bakshi N, Wang YF, Gonzalez MD, Adamkiewicz TV, Yildirim I, Lane PA.   +10 more
europepmc   +1 more source

A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18-64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8. [PDF]

Clin Infect Dis
Scott PT, Pathirana J, Kato A, Tytus R, Perez CM, Gilchrist NL, Kanou H, Ha Yoo K, Kania G, Nissen M, Russell AF, Fernsler D, Waleed M, Li J, Buchwald UK, Platt HL.   +15 more
europepmc   +1 more source

Recent Advances in Pneumococcal Conjugate Vaccines: A 13-Valent Pneumococcal Conjugate Vaccine

Journal of Pediatric Infection, 2011
openaire   +1 more source

Evaluating the effectiveness of the 13-valent pneumococcal conjugate vaccine and clinical and demographic characteristics on pneumococcal carriage density in young children in Papua New Guinea, Lao PDR, and Mongolia. [PDF]

BMC Infect Dis
von Mollendorf C, Jagne I, Ashley EA, Blyth CC, Chan J, Ford RL, Mayxay M, Mulholland EK, Mungun T, Narangerel D, Tundev O, Nation ML, Nguyen CD, Ortika BD, Pell CL, Sapura J, Vilivong K, Lai J, Zhang Y, Dance DAB, Pomat WS, Satzke C, Russell FM, PneuCaPTIVE Research Group.   +23 more
europepmc   +1 more source

Clinical and evidence-based considerations for choosing a pneumococcal conjugate vaccine in India: A narrative review. [PDF]

Hum Vaccin Immunother
Yewale V, Chatterjee P, Marathe SM, Taur S, Sathyanarayanan S.   +4 more
europepmc   +1 more source

Immunogenicity and safety of biological E's 14-valent pneumococcal conjugate vaccine (PNEUBEVAX 14®) administered in a 2p + 1 schedule to healthy infants: a multicenter, randomized, active controlled, single-blind, phase III trial. [PDF]

Lancet Reg Health Southeast Asia
Thuluva S, Matur RV, Gunneri S, Ningaiah S, Yerroju V, Mogulla RR, Dhar C, Thammireddy K, Paliwal P, Kawade A, Nanjappa P, Pramod J, Narang M, Chakravarthy BS, Virupakashappa PM.   +14 more
europepmc   +1 more source

Pneumococcal serotype distribution and outcomes in cancer patients with community-acquired pneumonia: A prospective study using the 15-valent pneumococcal conjugate vaccine serotype specific urinary antigen detection assay. [PDF]

Int J Infect Dis
Cintrón M, Gali V, Li Y, Jani K, Cander S, Kaltsas A, Kamboj M, Seo SK, Papanicolaou GA, Lee YJ.   +9 more
europepmc   +1 more source

Cost-effectiveness of a 13-valent pneumococcal conjugate vaccine compared with currently available pneumococcal conjugate vaccines in Indian children. [PDF]

IJID Reg
Taur SR, Rampal R, Sathyanarayanan S, Nahdi FB, Wannaadisai W, Fletcher MA, Huang L.   +6 more
europepmc   +1 more source